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Methods From January 2012 to December 2013, patients who underwent
RFA of cavotricuspid isthmus for typical atrial flutter in our centre were
retrospectively included.
Results Of 166 patients (137 men, mean age: 66.7±10 years), 61 (36.7%)
had a history of AF. 
The mean CHA2DS2VASc and HASBLED scores were 2.49 and 1.11. 
Mean left ventricular ejection fraction was 53±13% and 77 (46.4%)
patients had a subsequent cardiomyopathy, whereas 61 (36.7%) had a history
of AF. Of 166 RFA, sinus rhythm was obtain in 160 patients and 141 (84.9%)
procedures were considered as a complete success (complete isthmus block).
During a mean follow up of 489±244 days, there were 7 (5%) and 9 (36%)
AFL recurrence in patients with and without isthmus block respectively. New-
onset or recurrent AF were experienced by 63 (39%) patients. 
History of AF was an independent predictive factor of AF (33 (52.4%) vs.
28 (27.2%) patients; p=0.002). 
The younger patients (64.4 ±11.7 vs. 68.2±9.9 years; p=0.03) and patients
with lower CHA2DS2VASc score had more AF post ablation (2.16±1.53 vs.
2.70±1.57; p=0.03).
Conclusion After successful RF ablation, AF was frequent in patients
especially in patient with AF history before AFL RFA, but also occurred in
patient with lone AFL. Age and CHA2DS2VASc score were inversely associ-
ated with onset of AF. Identify AF and risk patients is crucial regarding to
long-term antithrombotic therapy.
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Goal to evaluate routine anesthesia strategy in ablation procedures by
French electrophysiologists (EPs). 
Method A questionnaire was e-mailed to 110 French EP. 
Results Answers were obtained from 95 EP (86.4%): 25% working in a
private center, 75% in a public center. Anesthesiologists are always available
in 70.8% of private centers vs 11.4% of public centers. When available, 54.2%
are entirely dedicated to electrophysiology in private vs 18.6% in public cen-
ters. When an anesthesiologist is not available, sedation is obtained using mid-
azolam associated with nalbuphin (32%), morphine (16%) or fentanyl (9%).
Propofol is used occasionally by 29% of EPs (35% in public, 9% in private
centers). Nitrous oxide inhalation gas is available in 40% of private and 34.3%
of public centers. Private EPs are satisfied with the anesthesiologist strategy in
100% of cases versus only 41% of public EP. A good or very good relation-
ship with anesthesiologists is declared by 92% of private EPs versus only 56%
of public EPs. 
Conclusions Collaboration of anesthesiologists with EPs seems to be
more operational in private centers. Deep sedation seems to be used as an
alternative when anesthesiologists are not available more often in public
centers. 
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Background Current ESC guidelines require anticoagulation with VKA in
patients with “valvular atrial fibrillation (AF)”, which includes all types of
prosthetic valve. We evaluated the value of the CHA2DS2 -VASc score for
thromboembolism risk assessment in AF patients with biological valve
replacement.
Methods and results Among 8962 patients with AF seen between 2000
and 2010, 8053 (90%) had "non-valvular AF” and 909 (10%) had valvular
AF. Patients with valvular AF had a biological prosthesis in 59% (n=549),
among which 77% (n=426) had a single aortic prosthesis and 64% (n=309)
received a VKA. Patients with aortic bioprosthesis were older and had a
higher CHA2DS2-VASc score than those with a mitral prosthesis or a
double valve replacement. During a follow up of 876±1048 days, 681
stroke/thromboembolic events were recorded. The occurrence of events
were similar in patients with bioprosthesis compared to the patients
without prosthesis: (hazard ratio HR 1.10, 95% CI 0.83-1.45, p=0.52).
Patients with aortic bioprosthesis tended to have a higher risk of embolic
events vs other AF patients with bioprosthesis (HR 1.73, 95% CI 0.87-
3.45), p=0.12). In multivariate analysis, older age and higher CHA2DS2-
VASC score were the only predictors of embolic events whilst the
presence of a bioprosthesis was not an independent predictor of events.
The CHA2DS2-VASC score predicted the embolism risk in AF patients
with a bioprosthesis (c-statistic 0.55 95% CI 0.47-0.63) but was less
efficient than in “non-valvular” AF patient (c-statistic 0.66, 95% CI 0.64-
0.67). 
Conclusion This “real world” results support the use of oral anti-
coagulation in AF patients who have bioprosthetic heart valves. It also
supports the use of CHA2DS2-VASc scoring for the risk evaluation of AF
patients with bioprostheses, albeit with reduced reliability. Patients with
aortic bioprosthesis had a non significant higher risk of embolic events. A
higher CHA2DS2-VASc score in these patients is likely to explain these
results.
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Abstract 0362 – Table: predictive factors of AF
No FA post ablation 
(N=103)
FA post ablation 
(N=63) 
p
Men/Women (N/N) 89/14 48/15 0.09
Age (years) 68.2+/–9.9 64.4+/–11.7 0.03*
SAS 10 (9.7) 4 (6.3) 0.57
Cardiopathy 53 (51.5) 24 (38.1) 0.11
History of AF (N [%]) 28 (27.2) 33 (52.4) 0.002*
Dilated LA (N [%]) 43 (41.7) 32 (50.8) 0.4
Dilated LV (N [%]) 12 (11.7) 12 (19) 0.41
LVEF <45% (N [%]) 29 (28.2) 10 (15.9) 0.09
High blood pressure 
(N [%]) 63 (61.2) 31 (49.2) 0.14
Age ≥75 years 29 (28.2) 15 (23.8) 0.59
Diabetes mellitus 18 (17.5) 9 (14.3) 0.66
CHA2DS2VASc 2.7+/–1.57 2.16+/–1.53 0.03*
BMI (kg/m2) 27.4+/–5.5 27.9+/–4.9 0.55
Creatinine clearance 
(Cockroft) 78.1+/–30.8 85.3+/–37.4 0.19
Creatinine clearance 
(MDRD) 72.8+/–22.4 73.9+/–23.7 0.76
SAS: sleep apnoea syndrome; AF: atrial fibrillation; LA: left atrial; LV: left 
ventricular
LVEF: left ventricular ejection fraction; BMI: body mass index
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Aim Radiofrequency catheter ablation (RFA) is an effective treatment for
symptomatic paroxysmal atrial fibrillation (AF). A multi-electrode ablation
catheter may used to achieve pulmonary vein isolation (PVI). The nMARQ
catheter is an innovative irrigated multi-electrode ablation catheter, associated
with the CARTO* system. The aim of our study was to describe the success
rate and complications associated with this system.
Methods Thirty-four consecutive procedures performed in our centre
were included in the study. All 34 patients had symptomatic paroxysmal
AF (mean age: 60±10 years, 68% of men). The ablation procedure
consisted in pulmonary vein isolation with the nMARQ system only.
Acute success was defined as complete electrophysiological pulmonary
vein isolation. Clinical success was defined as freedom from symptomatic
AF or atrial arrhythmia after a period of at least 3 months. All complica-
tions were recorded.
Results Thirty-four patients with paroxysmal AF were included in the
study. Total duration of the procedure was (mean±SD): 89±18min and flu-
oroscopy time: 3±1 min. Mean RFA application duration was 10±3 min.
Electrophysiological isolation was obtained in 99% of the 131 pulmonary
veins. A common left pulmonary vein was found in 4 patients, and the
inferior pulmonary vein was not isolated in one patient because of catheter
unstability. A significant complication occured in two patients (6%). These
two complications were a groin vascular injury. After a single procedure
at a mean follow-up of 10 months, 85% patients remained free of symp-
tomatic AF. 
Conclusion The multipolar ablation irrigated catheter (nMARQ) is an
effective and safe system to achieve PVI, with short procedure and fluoros-
copy times.
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Background Ablation of paroxysmal atrial fibrillation (PAF) using a cryo-
balloon catheter is currently expanding. The success rate of ablation with the
Arctic Front® cryoballoon has been found to be similar to what was observed
with radiofrequency catheter.The recent use of the new catheter Arctic Front
Advance® seems to improve this performances. We postulate that this new
generation of catheter could decrease the rate of redo procedures and maintain
more effectively the pulmonary vein (PV) isolation.
Methods From January 2009 to April 2014, we prospectively collected
data regarding all consecutive patients referred for PAF ablation with cryob-
alloon technology at our institution. Patients were assigned either to 1stCB
group if the arctic front catheter was used (from January 2009 to June 2012)
or to the 2ndCB group if the arctic front advance catheter was used (from jully
2012 to April 2014). We performed a follow up of one year in each group and
we compared the number of redo procedures and their characteristics.
Results We included 106 patients in borh groups.Characteristics of the
population are described in table 1. The rate of redo procedures at one year
was significantly lower in the 2ndCB group (9.4% vs 37%; p<0.01).
When a redo procedure was performed, the average number of reconnected
PV was 2.2 in the 2ndCB group and 2.8 in 1stCB group (p=0.14). In the
2ndCB group, PV reconnection occurred more frequently the inferior PVs
(right inferior PV=90%, left inferior PV=63%, right superior PV 30% and left
superior PV=15%). This difference of distribution is less pronounced in the
1stCB group (LIPV=90%, RIPV=65%, RSPV=58% and the LSPV=55%).
Conclusion The new generation of cryoballoon significantly decreased the
rate of redo procedures at one year. Using the second generation CB, pulmonary
vein reconnection was more frequently observed with the inferior PV. This could
probably be explained by the anatomical characteristics of these veins (figure next
page). 
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Abstract 0455 – Figure: Example of RF application using N-MARQ system
